This joint-specific response pattern was consistent across all advanced treatment modalities, including abatacept, interleukin-6 receptor inhibitors, Janus kinase inhibitors, rituximab and TNFi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results